A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.

• Main Authors: Mohamed Osman (Author), Anoop Mistry (Author), Ada Keding (Author), Rhian Gabe (Author), Elizabeth Cook (Author), Sarah Forrester (Author), Rebecca Wiggins (Author), Stefania Di Marco (Author), Stefano Colloca (Author), Loredana Siani (Author), Riccardo Cortese (Author), Deborah F Smith (Author), Toni Aebischer (Author), Paul M Kaye (Author), Charles J Lacey (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2017-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Visceral leishmaniasis (VL or kala azar) is the most serious form of human leishmaniasis, responsible for over 20,000 deaths annually, and post kala azar dermal leishmaniasis (PKDL) is a stigmatizing skin condition that often occurs in patients after successful treatment for VL. Lack of effective or...